HKHiroto Katoh

Hiroto Katoh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hiroto Katoh has a total of 179 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Duocarmycin‐Bearing Antibody‐Mimetic Drug Conjugate Combined With an ATR Inhibitor Results in Complete Tumor Regression in a KPL ‐4 Xenograft Model

    by Toshiya Tanaka, Akira Sugiyama, Juri Sakata, Toshifumi Tatsumi, Hiroto Katoh, Keisuke Maeda, Yuya Inagaki, Takefumi Yamashita, Takeshi Kawamura, Mayu Kuratani, et al.

    Antibody–drug conjugates (ADCs) have demonstrated superior clinical outcomes in patients with HER2‐positive advanced breast cancer compared with previous treatment modalities. However, resistance and treatment‐limiting toxicities frequently emerge during repeated administration, underscoring an unmet need for strategies to overcome ADC failure. In this study, we investigated whether inhibition of ataxia telangiectasia and Rad3‐related protein (ATR) could enhance the antitumor efficacy of antibody‐mimetic drug conjugates (AMDCs), a targeted payload delivery platform. Combination treatment with a duocarmycin‐bearing HER2‐targeted AMDC (Duo‐HER2) and an ATR inhibitor markedly enhanced antitumor activity in a human HER2‐positive breast cancer xenograft model. In a limited cohort of treated mice, this combination induced sustained tumor suppression, with prolonged tumor‐free survival exceeding 100 days. Although transient body weight loss was observed during the early phase of treatment, no evidence of overt systemic toxicity was detected. Synergistic interactions with Duo‐HER2 were further confirmed in vitro using three clinically relevant ATR inhibitors—tuvusertib, ceralasertib, and berzosertib. Short‐term apoptosis analyses revealed only modest induction of cell death, whereas longer‐term viability assays demonstrated pronounced growth suppression. Cell cycle analyses showed S‐phase accumulation accompanied by a mild increase in the sub‐G1 population, suggesting that the combination initially exerts a cytostatic effect through replication stress–induced S‐phase arrest, followed by delayed cytotoxicity. Together, these findings indicate that Duo‐HER2 combined with ATR inhibitors synergistically suppresses tumor growth in HER2‐positive breast cancer models. Further studies employing optimized formulations, expanded in vivo cohorts, and additional tumor models will be required to fully define the therapeutic potential of this strategy and its relevance for overcoming ADC resistance.

  • Open Access

    Sequential omics analysis reveals molecular signatures of malignant transformation in recurrent meningiomas

    by Kenta Ohara, Satoru Miyawaki, Yu Teranishi, Daisuke Komura, Atsushi Okano, Hiroki Hongo, Shogo Dofuku, Daiichiro Ishigami, Yu Sakai, Daisuke Shimada, et al.

    Meningiomas are the most common primary brain tumors in adults and have the potential for recurrence. Although most recurrent meningiomas retain their initial World Health Organization grade, a subset undergoes malignant transformation (MT). The molecular mechanisms underlying this transformation remain poorly understood. We aimed to characterize distinct recurrence subtypes—MT and grade 1-retained recurrence (GR)—using sequential multi-omic analyses. In this study, we reviewed meningioma patients with paired histological evaluations. Among these, 10 patients experienced MT and 25 showed GR. Patients with MT exhibited significantly higher Ki-67 proliferation indices and shorter overall survival. Comprehensive molecular profiling, including matched sequential recurrences, was performed on samples from six patients each with MT and GR meningiomas. Compared to GR tumors, MT tumors demonstrated a marked increase in tumor mutation burden and copy number alterations, with deletion of cyclin-dependent kinase inhibitor 2A emerging as a key acquired event. MT cases also showed selective upregulation of cell cycle-related genes, including Forkhead box M1, a feature absent in GR tumors. Notably, even prior to recurrence, MT tumors displayed distinct global DNA methylation patterns, particularly in regions targeted by the polycomb repressive complex 2 and H3K27me3 marks. Our findings suggest that molecular signatures evolve during MT and that certain intermediate aggressive meningiomas may progress toward malignancy. This study underscores the importance of DNA methylation and transcriptomic profiling in understanding tumor progression and recurrence. While molecular profiling holds promise for prognostication, further research is needed to identify key drivers of MT and clarify their roles in meningioma pathogenesis.


  • Open Access

    Molecular mimicry-driven autoimmunity in chronic rhinosinusitis with nasal polyps

    by Tomoaki Asamori, Hiroto Katoh, Mikiya Takata, Daisuke Komura, Miwako Kakiuchi, Itaru Hashimoto, Madoka Sakurai, Asami Yamamoto, Takeshi Tsutsumi, Takahiro Asakage, et al.


  • Open Access

    APRIL / BAFF upregulation is associated with clonal B‐cell expansion in Hunner‐type interstitial cystitis

    by Masafumi Horie, Yoshiyuki Akiyama, Hiroto Katoh, Satoru Taguchi, Masaki Nakamura, Keishi Mizuguchi, Yukinobu Ito, Takashi Matsushita, Tetsuo Ushiku, Shumpei Ishikawa, et al.

    Hunner‐type interstitial cystitis (HIC) is a chronic inflammatory disease of the urinary bladder with an unknown etiology. We conducted comprehensive immunogenomic profiling of bladder specimens obtained by biopsy and cystectomy from 37 patients with HIC. Next‐generation RNA sequencing demonstrated abundant plasma cell infiltration with frequent light chain restriction in HIC‐affected bladder tissue. Subsequent analysis of the B‐cell receptor repertoire revealed spatial and temporal expansion of B‐cell clones. The extent of B‐cell clonal expansion was significantly correlated with the gene expression levels of TNFSF13 and TNFSF13B , which encode APRIL and BAFF, respectively. These findings indicate that APRIL and BAFF are the key regulators of clonal B‐cell expansion in HIC and might serve as therapeutic targets in this debilitating disease. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.


  • Open Access

    SegRep: Mask-Supervised Learning for Segment Representation in Pathology Images

    by Chichun Yang, Daisuke Komura, Mieko Ochi, Miwako Kakiuchi, Hiroto Katoh, Tetsuo Ushiku, Shumpei Ishikawa

    In pathology, various tissue and cell components play diverse biological roles. The morphology of each component can vary markedly with differentiation status or pathological conditions, making it critical for understanding diseases. Traditional computational pathology methods typically employ patch-based feature extraction, which aggregates visual features across entire images. However, this approach does not differentiate between tissue types, limiting component analysis. To address this limitation, we introduce a novel concept in pathology image analysis, namely segment representation learning, and present an algorithm, SegRep, for this purpose. SegRep uses a unique dual-masking strategy that combines input masking and feature map masking. This approach effectively removes external influences for the targeted segment, identified via a segmentation model or manual annotation, allowing for the extraction of segmentspecific feature representations. In addition, SegRep utilizes a self-supervised learning algorithm to achieve optimized segment representation. We evaluated SegRep’s efficacy in clustering and classification tasks using a dataset of human gastric cancer samples. The results demonstrate SegRep’s superior capability in extracting feature vectors that are highly specific to different pathology image segments. Compared with traditional methods, SegRep shows significant improvements in accuracy and specificity in both clustering and classification tasks. Segment representations obtained via SegRep can offer a more detailed and insightful perspective on computational pathology, paving the way for advanced applications in the field.

  • Open Access

    High‐throughput system for the thermostability analysis of proteins

    by Sae Ito, Ryo Matsunaga, Makoto Nakakido, Daisuke Komura, Hiroto Katoh, Shumpei Ishikawa, Kouhei Tsumoto

    Thermal stability of proteins is a primary metric for evaluating their physical properties. Although researchers attempted to predict it using machine learning frameworks, their performance has been dependent on the quality and quantity of published data. This is due to the technical limitation that thermodynamic characterization of protein denaturation by fluorescence or calorimetry in a high‐throughput manner has been challenging. Obtaining a melting curve that derives solely from the target protein requires laborious purification, making it far from practical to prepare a hundred or more samples in a single workflow. Here, we aimed to overcome this throughput limitation by leveraging the high protein secretion efficacy of Brevibacillus and consecutive treatment with plate‐scale purification methodologies. By handling the entire process of expression, purification, and analysis on a per‐plate basis, we enabled the direct observation of protein denaturation in 384 samples within 4 days. To demonstrate a practical application of the system, we conducted a comprehensive analysis of 186 single mutants of a single‐chain variable fragment of nivolumab, harvesting the melting temperature (Tm) ranging from −9.3 up to +10.8°C compared to the wild‐type sequence. Our findings will allow for data‐driven stabilization in protein design and streamlining the rational approaches.


  • Top Cited Papers

    Multiancestry genomic and transcriptomic analysis of gastric cancer

    by Yasushi Totoki, Mihoko Saito-Adachi, Yuichi Shiraishi, Daisuke Komura, Hiromi Nakamura, Akihiro Suzuki, Kenji Tatsuno, Hirofumi Rokutan, Natsuko Hama, Shogo Yamamoto, et al.

    Gastric cancer is among the most common malignancies worldwide, characterized by geographical, epidemiological and histological heterogeneity. Here, we report an extensive, multiancestral landscape of driver events in gastric cancer, involving 1,335 cases. Seventy-seven significantly mutated genes (SMGs) were identified, including ARHGAP5 and TRIM49C. We also identified subtype-specific drivers, including PIGR and SOX9, which were enriched in the diffuse subtype of the disease. SMGs also varied according to Epstein–Barr virus infection status and ancestry. Non-protein-truncating CDH1 mutations, which are characterized by in-frame splicing alterations, targeted localized extracellular domains and uniquely occurred in sporadic diffuse-type cases. In patients with gastric cancer with East Asian ancestry, our data suggested a link between alcohol consumption or metabolism and the development of RHOA mutations. Moreover, mutations with potential roles in immune evasion were identified. Overall, these data provide comprehensive insights into the molecular landscape of gastric cancer across various subtypes and ancestries.


  • Open Access

    Immune repertoire profiling for disease pathobiology

    by Hiroto Katoh, Daisuke Komura, Genta Furuya, Shumpei Ishikawa

    Lymphocytes consist of highly heterogeneous populations, each expressing a specific cell surface receptor corresponding to a particular antigen. Lymphocytes are both the cause and regulator of various diseases, including autoimmune/allergic diseases, lifestyle diseases, neurodegenerative diseases, and cancers. Recently, immune repertoire sequencing has attracted much attention because it helps obtain global profiles of the immune receptor sequences of infiltrating T and B cells in specimens. Immune repertoire sequencing not only helps deepen our understanding of the molecular mechanisms of immune‐related pathology but also assists in discovering novel therapeutic modalities for diseases, thereby shedding colorful light on otherwise tiny monotonous cells when observed under a microscope. In this review article, we introduce and detail the background and methodology of immune repertoire sequencing and summarize recent scientific achievements in association with human diseases. Future perspectives on this genetic technique in the field of histopathological research will also be discussed.


  • Open Access

    Nucleic acid–triggered tumoral immunity propagates pH‐selective therapeutic antibodies through tumor‐driven epitope spreading

    by Genta Furuya, Hiroto Katoh, Shinichiro Atsumi, Itaru Hashimoto, Daisuke Komura, Ryo Hatanaka, Shogo Senga, Shuto Hayashi, Shoji Akita, Hirofumi Matsumura, et al.

    Important roles of humoral tumor immunity are often pointed out; however, precise profiles of dominant antigens and developmental mechanisms remain elusive. We systematically investigated the humoral antigens of dominant intratumor immunoglobulin clones found in human cancers. We found that approximately half of the corresponding antigens were restricted to strongly and densely negatively charged polymers, resulting in simultaneous reactivities of the antibodies to both densely sulfated glycosaminoglycans (dsGAGs) and nucleic acids (NAs). These anti‐dsGAG/NA antibodies matured and expanded via intratumoral immunological driving force of innate immunity via NAs. These human cancer–derived antibodies exhibited acidic pH–selective affinity across both antigens and showed specific reactivity to diverse spectrums of human tumor cells. The antibody‐drug conjugate exerted therapeutic effects against multiple cancers in vivo by targeting cell surface dsGAG antigens. This study reveals that intratumoral immunological reactions propagate tumor‐oriented immunoglobulin clones and demonstrates a new therapeutic modality for the universal treatment of human malignancies.


  • Open Access

    Pathological complete remission of relapsed tumor by photo‐activating antibody–mimetic drug conjugate treatment

    by Yudai Kaneko, Kenzo Yamatsugu, Takefumi Yamashita, Kazuki Takahashi, Toshiya Tanaka, Sho Aki, Toshifumi Tatsumi, Takeshi Kawamura, Mai Miura, Masazumi Ishii, et al.

    Antibody-mimetic drug conjugate is a novel noncovalent conjugate consisting of an antibody-mimetic recognizing a target molecule on the cancer cell surface and low-molecular-weight payloads that kill the cancer cells. In this study, the efficacy of a photo-activating antibody-mimetic drug conjugate targeting HER2-expressing tumors was evaluated in mice, by using the affibody that recognize HER2 (Z(HER2:342)) as a target molecule and an axially substituted silicon phthalocyanine (a novel potent photo-activating compound) as a payload. The first treatment with the photo-activating antibody-mimetic drug conjugates reduced the size of all HER2-expressing KPL-4 xenograft tumors macroscopically. However, during the observation period, relapsed tumors gradually appeared in approximately 50% of the animals. To evaluate the efficacy of repeated antibody-mimetic drug conjugate treatment, animals with relapsed tumors were treated again with the same regimen. After the second observation period, the mouse tissues were examined histopathologically. Unexpectedly, all relapsed tumors were eradicated, and all animals were diagnosed with pathological complete remission. After the second treatment, skin wounds healed rapidly, and no significant side effects were observed in other organs, except for occasional microscopic granulomatous tissues beneath the serosa of the liver in a few mice. Repeated treatments seemed to be well tolerated. These results indicate the promising efficacy of the repeated photo-activating antibody-mimetic drug conjugate treatment against HER2-expressing tumors.